Benchmark initiated coverage of Kamada (KMDA) with a Buy rating and $15 price target Kamada has expanded its specialty plasma-derived product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback